HER2 Breast Cancer

Promising findings from the phase 2 ELAINE-1 and ELAINE-2 trials have led to the start of a phase 3 study where investigators will evaluate lasofoxifene and abemaciclib as a treatment for patients with ER-positive/HER2-negative breast cancer and an ESR1 mutation.

In season 4, episode 2 of Targeted Talks, Sara A. Hurvitz, MD, discusses key advances in the HER2-positive breast cancer space and interesting ongoing research, namely trastuzumab deruxtecan.

Experts addressed ARX788 for patients with HER2-positive breast cancer, and a data update from the update for APEX-01 evaluating ARX517 in patients with prostate cancer was provided during a virtual analyst and investor day.

In the biomarker analysis of the phase 3 NeoALTTO study, a small reduction in antimüllerian hormone levels were seen during 2 weeks of anti-HER2 treatment alone followed by a significant decline in most patients with HER2-positive breast cancer after combining with weekly paclitaxel.

Findings from the DEBBRAH trial showed that the use of trastuzumab deruxtecan in patients with HER2-positive advanced breast cancer showed promising efficacy for those with brain metastases.

New clinical trial data have shown that patients with IHC 1+ or IHC 2+/ISH– disease, but no ERBB2 amplification, could still benefit from HER2 targeted therapies.

In the phase 1b/2 DESTINY-Breast07 study, positive results were shown with trastuzumab deruxtecan, even without the addition of pertuzumab.

The use of trastuzumab deruxtecan in the neoadjuvant setting showed promising responses in patients with early-stage breast cancer.

Patients with advanced HER2-positive breast cancer had better progression-free and overall survival outcomes when given trastuzumab deruxtecan versus capecitabin-based treatment.

Trastuzumab deruxtecan demonstrated a clinically meaningful and statistically significant improvement in overall versus TDM-1 as well as a continued PFS benefit, according to Sara A. Hurvitz, MD.

TAC01-HER2 elicited encouraging safety and clinical activity in patients with HER2-positive solid tumors with no dose limiting toxicities, cytokine release syndrome, or immune effector cell-associated neurotoxicity observed.

During a Targeted Oncology case-based roundtable event, Jennifer M. Matro, MD, discussed the data supporting systemic therapies for treatment of early-stage HER2-positive breast cancer including trastuzumab and pertuzumab.

Pertuzumab plus trastuzumab and chemotherapy remains the standard of care for HER2-positive breast cancer, after the addition of atezolizumab did not benefit responses in the Impassion050 study.

In season 3, episode 8 of Targeted Talks, Christie J. Hilton, DO, discusses treating first- and second-line HER2-positive breast cancer.

Adding abemaciclib to trastuzumab improved overall survival in women with with hormone receptor–positive, HER2-positive advanced breast cancer, according to new findings discussed at the 2022 ESMO Congress.

Erika P. Hamilton, MD, discusses how researchers are addressing unmet needs for patients with HER2-positive breast cancer.

Findings from the phase 2 DESTINY-Breast02 show that trastuzumab deruxtecan improves both progression-free and overall survival in patients with HER2-positive unresectable and/or metastatic breast cancer.

Investigators continue to explore possible systemic treatment options that could improve disease control for patients with brain metastases derived from breast cancer.

Results from the DS8201-A-U105 study showed that nivolumab added to trastuzumab deruxtecan has some benefit for patients with HER2-positive breast cancer.

Harnessing existing and otherwise safe antibody-targeting strategies and combining them with chemotherapy or other bioactive compounds or as a bispecific dual antibody moiety are an exciting strategy of protein engineering that is emerging and coming into its own in oncology.

Results from the SUMMIT basket study revealed encouraging results with the triplet regimen in patients with HR-positive/HER2-negative MBC compared with other variations and monotherapies of the 3 drugs.

Findings from the phase 3 APHINITY study show that the combination pertuzumab, trastuzumab, and chemotherapy improves invasive disease-free survival compared with trastuzumab and chemotherapy alone in patients with lymph node-positive, HER2-positive early breast cancer.

Visits to the phase 3 FLAMINGO-01 clinical trial sites have been initiated following the lift of a FDA clinical hold.

Based on findings from the TULIP study, [vic-] trastuzumab duocarmazine may be a new standard treatment option for patients with HER2-positive unresectable locally advanced metastatic breast cancer. a biologics license application has been accepted by the FDA.

Neil Vasan, MD, PhD, discusses how past studies have supported de-escalated approaches and other improvements to treatment for patients with HER2-positive breast cancer.